先进制造业知识服务平台
国家科技图书文献中心机械分馆  工信部产业技术基础公共服务平台  国家中小企业公共服务示范平台

OA期刊


ISSN1942-0862
刊名Mabs
出版商Taylor & Francis Inc.
urlhttps://www.tandfonline.com/loi/kmab20
机构Taylor & Francis Ltd.



全部

2010 2011 2012 2013 2014 2015
2016 2017 2018 2019 2020 2021
2022 2023 2024 2025

2024, vol.16, no.1 2024, vol.16, no.10 2024, vol.16, no.11 2024, vol.16, no.12 2024, vol.16, no.2 2024, vol.16, no.3
2024, vol.16, no.4 2024, vol.16, no.5 2024, vol.16, no.6 2024, vol.16, no.7 2024, vol.16, no.8 2024, vol.16, no.9

题名作者出版年年卷期
Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflowsTushar Jain;Bianka Prinz;Alexander Marker;Alexander Michel;Katrin Reichel;Valerie Czepczor;Sylvie Klieber;Wei Sun;Sagar Kathuria;Sevim Oezguer Bruederle;Christian Lange;Lena Wahl;Charles Starr;Alessandro Masiero;Lindsay Avery;20242024, vol.16, no.7
Modulation of the high concentration viscosity of IgG1 antibodies using clinically validated Fc mutationsJoel Heisler;Daniel Kovner;Saeed Izadi;Jonathan Zarzar;Paul J. Carter;20242024, vol.16, no.7
Identification of novel anti-CD16a antibody clones for the development of effective natural killer cell engagers 20242024, vol.16, no.7
Rapid depletion of “catch-and-release” anti-ASGR1 antibody in vivoSiva Charan Devanaboyina;Peng Li;Edward L. LaGory;Carrie Poon-Andersen;Kevin D. Cook;Marcus Soto;Zhe Wang;Khue Dang;Craig Uyeda;Ryan B. Case;Veena A. Thomas;Ronya Primack;Manuel Ponce;Mei Di;Brian Ouyang;Joelle Kaner;Sheung Kwan Lam;Mina Mostafavi;20242024, vol.16, no.7
Discovery and development of ANV419, an IL-2/anti-IL-2 antibody fusion protein with potent CD8+ T and natural killer cell-stimulating capacity for cancer immunotherapyPatrizia Murer;Barbara Brannetti;Jean-Michel Rondeau;Laetitia Petersen;Nicole Egli;Simone Popp;Catherine Regnier;Kirsten Richter;Andreas Katopodis;Christoph Huber;20242024, vol.16, no.7
Quantifying LAGA mutated mouse IgG2a monoclonal antibody with a rapid pepsin digestion enabled immunoaffinity LC/MS/MS assayLinlin Dong;Susan Chen;Konstantin Piatkov;Dong Wei;Mark G. Qian;20242024, vol.16, no.7
Illuminating a biologics development challenge: systematic characterization of CHO cell-derived hydrolases identified in monoclonal antibody formulationsMelanie Maier;Linus Weiß;Nikolas Zeh;Valerie Schmieder-Todtenhaupt;Alireza Dehghani;Marius Nicolaus Felix;Daniel Heinzelmann;Benjamin Lindner;Moritz Schmidt;Joey Studts;Patrick Schulz;Bernd Reisinger;Kerstin Otte;Matthias Franzreb;Daniel Lakatos;Simon Fischer;20242024, vol.16, no.7
Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapyAmelia C. McCue;Stephen J. Demarest;Karen J. Froning;Michael J. Hickey;Stephen Antonysamy;Brian Kuhlman;20242024, vol.16, no.7
The history and potential future of monoclonal antibody therapeutics development and manufacturing in four erasBrian Kelley;20242024, vol.16, no.7
Early determination of potential critical quality attributes of therapeutic antibodies in developability studies through surface plasmon resonance-based relative binding activity assessmentShuai Wang;Yanqiu Wang;Zhenzhen Li;Ye Hong;Zhaohui Wang;Jiteng Fan;Qiong Wang;Yuanjie Ge;Xiaofeng Zhao;Guangcun Cheng;Changyan Chen;Yadan Wu;Yayuan Fu;20242024, vol.16, no.7